Drugs / LAYLA
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT01768468 | Oct 2012 → Jun 2013 | osteoarthritis, knee | PMG Pharm Co., Ltd | Completed | Met primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Layla | “ETHNOPHARMACOLOGICAL RELEVANCE: This prospective, randomized, double-blinded, double-dummy, multicenter study compared the efficacy and safety of PG201 (Layla®), a new product...” PMID 26821189 ↗ Jan 2016 |
| Known as | PG201 | “ETHNOPHARMACOLOGICAL RELEVANCE: This prospective, randomized, double-blinded, double-dummy, multicenter study compared the efficacy and safety of PG201 (Layla®), a new product...” PMID 26821189 ↗ Jan 2016 |
| Modality | Traditional medicine (herbal / TCM) | “PG201 (Layla®), a new product from extracts of 12 plant sources” PMID 26821189 ↗ Jan 2016 |